Safety signals of perfluorohexyloctane ophthalmic solution in patients with dry eye disease - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluation of Safety Indicators for Perfluorohexyloctane Ophthalmic Solution in Individuals with Dry Eye Disease

  • By

  • Zhengtai Sun

  • Yuting Liu

  • Lijuan Que

  • May 28, 2026

Share

  • 1

    The study evaluated the safety of perfluorohexyloctane ophthalmic solution for dry eye disease using the FDA Adverse Event Reporting System (FAERS) database.

  • 2

    A total of 92 adverse event reports were identified, with the most common issues being product delivery mechanism problems and eye irritation.

  • 3

    The top adverse events meeting positive signal criteria included wrong dose and patient dissatisfaction with treatment.

  • 4

    The median time-to-onset for adverse events related to perfluorohexyloctane was 2 days.

  • 5

    FAERS data did not indicate major safety concerns, with reported adverse events primarily linked to the instillation process.

Original Source(s)

Safety signals of perfluorohexyloctane ophthalmic solution in patients with dry eye disease

  • by Zhengtai Sun, Yuting Liu, Lijuan Que

  • May 28, 2026

Related Content

Insights into the quality and guideline consistency of dry eye disease treatment videos on Chinese short-video platforms

Comparative study of the therapeutic effects of different medications on DM-associated dry eye syndrome after vitrectomy

Assessment of the aggregate index of systemic inflammation in dyslipidemia with dry eye disease: a retrospective case-control